Sequential therapy; a new treatment for Helicobacter pylori infection: But is it ready for general use?

Digestive and Liver Disease

Volumn 36, Issue 5, 2004, Pages 311-314

  De Boer, W A ^a   Kuipers, E J ^b   Kusters, J G ^b  

^a BERNHOVEN HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; TETRACYCLINE; TINIDAZOLE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; BISMUTH; DRUG DERIVATIVE; PROTON PUMP; RANITIDINE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; CLINICAL TRIAL; DIAGNOSTIC TEST; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION RATE; MEDICAL DOCUMENTATION; NONHUMAN; NOTE; PATIENT COMPLIANCE; PENICILLIN ALLERGY; PRESCRIPTION; SIDE EFFECT; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; BISMUTH; CLARITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; PROTON PUMPS; RANITIDINE; TETRACYCLINE;

EID: 4544310641     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2004.01.016     Document Type: Note

References (30)

1. Chiba N, Veldhuyzen van Zanten SJO, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positives (CAOET-Hp) randomised controlled trial. Br Med J 2002;324:1012-6.
2. Farkkilla MA, Sarna S, Valtonen V, Sipponen P. "Test & treat" strategy for management of uninvestigated dyspepsia in primary healthcare. Gastroenterology 2000;118:A438.
3. de Boer WA. Helicobacter pylori and dyspepsia strategies-debate: Yes, a test-and-treat strategy is a viable option in primary care. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori basic mechanisms to clinical cure 2002. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2002. p. 283-95.
4. Arents NLA, Thys JC, Kleibeuker JH. A rational Approach to uninvestigated dyspepsia in primary care. Review of the literature. Postgrad Med J 2002;78:707-16.
5. Malfertheiner P, Megraud F, O'Morain C, Hungin APS, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002;16:167-80.
6. de Boer WA, Tytgat GNJ. Clinical review. Treatment of Helicobacter pylori infection. Br Med J 2000;320:31-4.
7. Vakil N, Fennerty B. Cost-effectiveness of H. pylori eradication regimens: efficacy vs. effectiveness. Gut 1997;41:A89.
8. Janssen MJR, van Oijen AHAM, Verbeek ALM, Jansen JBMJ, de Boer WA. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Aliment Pharmacol Ther 2001;15:613-24.
9. Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares JM. Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy. Aliment Pharmacol Ther 2000;14:1141-50.
10. Della Monica P, Lavagna A, Masoero G, Lombardo L, Crocella L, Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002;16:1269-75.
11. de Boer WA, Tytgat GNJ. Should anti-Helicobacter therapy be different in patients with dyspepsia compared with patients with peptic ulcer diathesis? Eur J Gastroenterol Hepatol 2001;13:1281-4.
12. Isomoto H, Furusu H, Morikawa T, Mizuta Y, Nishiyama T, Omagari K, et al. 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxycillin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:1619-23.
13. Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998;115:1278-82.
14. Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001;357:1851-3.
15. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pre-treatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy. A meta-analytical approach. Dig Dis Sci 2000;45:68-76.
16. de Boer WA. Quadruple therapy. Second- or first-line eradication regimen? In: Scarpignato C, Bianchi Porro G, editors. Clinical pharmacology and therapy of Helicobacter pylori infection. Progress in basic and clinical pharmacology, vol. 11. Basel: Karger; 1999. p. 212-26.
17. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001;36:690-700.
18. de Boer WA. Strategies for therapy failures: Choice of "back-up"-regimen determined by primary treatment for Helicobacter pylori infection. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori basic mechanisms to clinical cure 2000. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2000. p. 609-21.
19. Seppala K, Kosunen TU, Nuutinen H, Sipponen P, Rautelin H, Sarna S, et al. Cure of Helicobacter pylori infection after failed primary treatment: one-center results from 120 patients. Scand J Gastroenterol 2000;35:929-34.
20. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the quadrate study. Gastroenterology 2002;123:1763-9.
21. Laine L, Hunt RH, El-Zimaity HMT, Nguyen B, Osato MS, Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole and tetracycline given with omeprazole versus omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomised, multicenter, North American Trial. Am J Gastroenterol 2003;98:562-7.
22. Calvet X, Ducons J, Guardiola J, Tito L, Andreu V, Bory F, et al. One-week triple versus quadruple therapy for Helicobacter pylori infection - a randomised trial. Aliment Pharmacol Ther 2002;16:1261-7.
23. Iakovenko EP, Grgoriev P, Yakovenko AV, Bikbavova R. Bismuth based regimens should be first line therapy for Helicobacter pylori. Gut 2002;51:A92.
24. van der Wouden EJ, Thys JC, van Zwet AA, Sluiter WJ, Kleibeuker H. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing Anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999;94:1751-9.
25. Kung NNS, Sung JJY, Yuen NWF, Ng PW, Wong KC, Chung ECH, et al. Anti-Helicobacter pylori treatment in bleeding ulcers: randomised controlled trial comparing 2-day versus 7-day bismuth quadruple therapy. Am J Gastroenterol 1997;92:438-41.
26. Theodors A, Thjodleifsson B, Bodvarsson A, Sigurdardottir G, Johannesson T. Can treatment of H. pylori infection be shortened? Multicentre study of four vs. seven days of treatment. Scand J Gastroenterol 2001;34(Suppl 233):20. Abstract 04.
27. de Boer WA. A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule. Exp Opin Invest Drugs 2001;10:1559-66.
28. Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17:719-26.
29. De Francesco V, Zullo A, Hassan C, Della Valle N, Pietrini L, Minenna MF, et al. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomized study. Dig Liver Dis 2004;36:322-6.
30. Graham DY, de Boer WA, Tytgat GNJ. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol 1996;91:1072-6.